On November 4, TH MEDICAL-B recorded an Intraday Rise of 16.66% in Regular Trading, with the stock trading at HK$52.05 and turnover reaching HK$241 million.

The move followed fresh market attention on the company’s puncture and ablation surgical robot, after a county-level hospital in Guizhou said it had introduced the system in 2025 and has since assisted nearly 100 patients with robot-guided puncture procedures, underscoring the product’s rollout potential at the grassroots level.

Additional context came from the company’s previously disclosed sales contract signed in late August to supply a puncture surgical navigation and positioning system to an independent third-party buyer for nearly RMB100 million, with deliveries to be made in stages. That order has been seen as a key marker of accelerating commercialization for the company’s core product line.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)